The drug has a black box warning about the risk of liver damage; specifically it can cause elevations in the levels of transaminases and causes fatty liver disease. In clinical trials, 18% of subjects taking<unk>  stopped using the drug due to adverse effects; the most common adverse effects leading to discontinuation were injection site reactions, increases of transaminases, flu-like symptoms (fever, chills, abdominal pain, nausea, vomiting), and abnormal liver tests. Other adverse effects include: heart problems including angina and palpitations, edema, pain in legs or arms, headache, insomnia, and hypertension.
Mipomersen
Acebutolol
Lumasiran
Eluxadoline
Mitapivat
Fabomotizole
Orlistat
Casimersen